Investor Presentation - First Six Months of 2021

79 Investor presentation First six months of 2021 Novo Nordisk's ambition within cardiovascular disease In-licensing/acquisition of mid-stage assets STATEN of prothena CORVIDIA BIOTECHNOLOGY C License agreement/partnership Heartseed Accelerate internal pipeline Subcutaneous PCSK9i - successful phase 1 results At least one product launched between 2024-2028 targeting atherosclerotic cardiovascular disease or heart failure with a highly innovative, first to market product serving a significant unmet need in a large patient population Novo NordiskⓇ

View entire presentation